arrow
P

Patrizia Zappasodi

vita-salute san raffaele university
H指数:24
被引数:2,167

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study

成人早期T细胞前体急性淋巴细胞白血病患者在接受儿科启发式GIMEMA LAL1913方案治疗后,早期同种异基因干细胞移植的积极结果。Campus ALL研究

2026-07-160
PRE
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
2026-01-130
OAAI
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
2025-11-120
PRE
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Venetoclax联合去甲基化药物作为异基因干细胞移植治疗复发/难治性急性髓系白血病的有效桥梁疗法:AVALON研究的一项亚组分析

2025-11-010
OAAI
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

培门冬酶(Pegaspargase)在55岁及以上急性淋巴细胞白血病患者的给药方案与耐受性研究:LAL1913方案的子分析,Campus ALL研究组。

2025-08-270
OAAI
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience

Gilteritinib在FLT3突变急性髓系白血病中的治疗:一项意大利真实世界经验

Cancer
IF5.1
2025-08-210
OAAI
Real World Incidence and Etiology of Infectious Complications in Adults With Ph-Negative Acute Lymphoblastic Leukemia Treated With the Pediatric-Inspired GIMEMA LAL1913 Program. A Campus All Study

真实世界中接受儿科启发式GIMEMA LAL1913方案治疗的Ph阴性急性淋巴细胞白血病成人患者的感染并发症发生率和病因学。一项Campus All研究

2025-08-110
OA
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

接受维奈克拉联合表观遗传药物治疗的患者的生存情况受治疗前合并症负担的影响

2025-01-200
OAAI
Unlocking Sanctuary Sites: The Efficacy of Brexucabtagene Autoleucel in Ocular B-ALL Relapse
2024-12-240
PRE
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial
2024-12-100
PRE
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in the Setting of the Gimema ALL2820 Trial

可测量残留病灶监测在Gimema ALL2820试验中针对费城染色体阳性急性淋巴细胞白血病(Ph plus ALL)的应用

BLOOD
IF23.1
2024-11-050
PRE
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
2024-08-152
OAAI
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
2023-08-119
OAAI
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

AVALON: 低甲基化药物联合维尼托克对新诊断或复发/难治性急性髓系白血病患者的现实疗效的意大利队列研究

CANCER
IF5.1
2023-01-2421
OAAI
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

继发感染使血液系统恶性肿瘤患者的新型冠状病毒肺炎结局恶化: it-hema-COV的报告

2022-08-127
OAAI
Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome
2022-01-240
PRE
Validation of the fitness criteria for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)
2021-05-0113
PREAI